The epidermal growth factor receptor (EGFR) plays a central role in regulating neoplastic
processes. The EGFR overexpression in many human epithelial tumors has been correlated …

Controlling the global COVID-19 pandemic depends, among other measures, on developing
preventive vaccines at an unprecedented pace. Vaccines approved for use and those in …

The development of recombinant COVID-19 vaccines has resulted from scientific progress
made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer…

Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …

Background As a first step towards a vaccine protecting COVID-19 convalescents from
reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods Thirty COVID-19 …

Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …

Background A phase 1, clinical trial to evaluate FINLAY-FR-1A vaccine in COVID-19
convalescent individuals was completed. Here, we report results of the phase 2, clinical trial. …

SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its
receptor-binding domain (RBD) with the host’s cellular receptor. Vaccines seek to block this …

Background The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the
target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two …